Table 1 Demographics and clinical characteristics of patients with HR+, HER2− early breast cancer at initial diagnosis
Characteristic | Overall | Node-Negative | 1–3 Positive Nodes | ≥4 Positive Nodes | ||||
|---|---|---|---|---|---|---|---|---|
All | Tested for Ki-67 | Not Tested for Ki-67 | All | Tested for Ki-67 | Not Tested for Ki-67 | |||
N | N = 567 | N = 212 | N = 48 | N = 164 | N = 258 | N = 61 | N = 197 | N = 97 |
Sex, n (%) | ||||||||
Female | 567 (100.0) | 212 (100.0) | 48 (100.0) | 164 (100.0) | 258 (100.0) | 61 (100.0) | 197 (100.0) | 97 (100.0) |
Mean agea [SD], years | 61.8 [12.7] | 64.1 [12.4] | 65.2 [12.0] | 63.7 [12.5] | 60.9 [12.8] | 61.8 [12.1] | 60.6 [13.0] | 59.2 [12.1] |
Race/Ethnicityb, n (%) | ||||||||
American Indian or Alaska Native | 1 (0.2) | 1 (0.5) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Asian | 3 (0.5) | 1 (0.5) | 0 (0.0) | 1 (0.6) | 2 (0.8) | 0 (0.0) | 2 (1.0) | 0 (0.0) |
Black or African American | 35 (6.2) | 10 (4.7) | 2 (4.2) | 8 (4.9) | 15 (5.8) | 3 (4.9) | 12 (6.1) | 10 (10.3) |
Hispanic or Latino | 21 (3.7) | 9 (4.2) | 4 (8.3) | 5 (3.0) | 6 (2.3) | 1 (1.6) | 5 (2.5) | 6 (6.2) |
Native Hawaiian or other Pacific Islander | 2 (0.4) | 2 (0.9) | 0 (0.0) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
White or Caucasian | 396 (69.8) | 147 (69.3) | 32 (66.7) | 115 (70.1) | 186 (72.1) | 42 (68.9) | 144 (73.1) | 63 (64.9) |
Other | 212 (37.4) | 76 (35.8) | 19 (39.6) | 57 (34.8) | 99 (38.4) | 22 (36.1) | 77 (39.1) | 37 (38.1) |
Unknown/Unspecified | 26 (4.6) | 13 (6.2) | 2 (4.2) | 11 (6.7) | 9 (3.5) | 4 (6.5) | 5 (2.5) | 4 (4.1) |
Menopausal status, n (%) | ||||||||
Postmenopause | 449 (79.2) | 175 (82.5) | 41 (85.4) | 134 (81.7) | 196 (76.0) | 47 (77.0) | 149 (75.6) | 78 (80.4) |
Premenopause | 118 (20.8) | 37 (17.5) | 7 (14.6) | 30 (18.3) | 62 (24.0) | 14 (23.0) | 48 (24.4) | 19 (19.6) |
Stage of diseasec, n (%) | ||||||||
Stage I | 56 (9.9) | 27 (12.7) | 9 (18.7) | 18 (11.0) | 29 (11.2) | 11 (18.0) | 18 (9.1) | 0 (0.0) |
Stage II | 370 (65.3) | 164 (77.4) | 35 (73.0) | 129 (78.7) | 191 (74.0) | 45 (73.8) | 146 (74.1) | 15 (15.5) |
Stage III | 126 (22.2) | 12 (5.6) | 4 (8.3) | 8 (4.8) | 35 (13.6) | 5 (8.2) | 30 (15.2) | 79 (81.5) |
Unknown | 15 (2.6) | 9 (4.2) | 0 (0.0) | 9 (5.5) | 3 (1.2) | 0 (0.0) | 3 (1.5) | 3 (3.1) |
Tumor sizec, n (%) | ||||||||
0–2 cm | 358 (63.1) | 105 (49.5) | 24 (50.0) | 81 (49.4) | 195 (75.6) | 43 (70.5) | 152 (77.2) | 58 (59.8) |
> 2 to < 5 cm | 155 (27.3) | 83 (39.1) | 20 (41.7) | 63 (38.4) | 48 (18.6) | 15 (24.6) | 33 (16.8) | 24 (24.7) |
≥ 5 cm | 28 (4.9) | 9 (4.2) | 2 (4.2) | 7 (4.3) | 8 (3.1) | 1 (1.6) | 7 (3.6) | 11 (1.3) |
Missing | 26 (4.6) | 15 (7.1) | 2 (4.2) | 13 (7.9) | 7 (2.7) | 2 (3.3) | 5 (2.5) | 4 (4.1) |
Number of positive nodesc, n (%) | ||||||||
0 | 212 (37.4) | 212 (100.0) | 48 (100.0) | 164 (100.0) | – | – | – | – |
1 | 150 (26.5) | – | – | – | 150 (58.1) | 32 (52.5) | 118 (59.9) | – |
2 | 79 (13.9) | – | – | – | 79 (30.6) | 24 (39.3) | 55 (27.9) | – |
3 | 29 (5.1) | – | – | – | 29 (11.2) | 5 (8.2) | 24 (12.2) | – |
≥ 4 | 97 (17.1) | – | – | – | – | – | – | 97 (100.0) |
Histologic gradec, n (%) | ||||||||
Grade 1 | 189 (33.3) | 74 (34.9) | 17 (35.4) | 57 (34.8) | 88 (34.1) | 21 (34.4) | 67 (34.0) | 27 (27.8) |
Grade 2 | 267 (47.1) | 86 (40.6) | 22 (45.8) | 64 (39.0) | 124 (48.1) | 32 (52.5) | 92 (46.7) | 57 (58.8) |
Grade 3 | 94 (16.6) | 43 (20.3) | 7 (14.6) | 36 (22.0) | 41 (15.9) | 8 (13.1) | 33 (16.8) | 10 (10.3) |
Unknown | 17 (3.0) | 9 (4.2) | 2 (4.2) | 7 (4.3) | 5 (1.9) | 0 (0.0) | 5 (2.5) | 3 (3.9) |